Datamonitor: Lilly reports encouraging survival data from Phase III cervical cancer trial - 1 views
-
Alexander Kühbach on 04 Jun 09Eli Lilly and Company has reported that Phase III trial data showed the addition of the company's Gemzar to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.
-
anonymous on 12 Sep 13The latest news in the world has ever seen. Recent and into atoms. Now present with us. Actual and reliable....NEWS TODAY www.killdo.de.gg